Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2108. 2008 Authors' conclusions Teriparatide (Forsteo®) is not recommended for use within NHS Wales for the treatment of osteoporosis in men at increased risk of fracture. Indexing Status Subject indexing assigned by CRD MeSH Bone Density Conservation Agents; Males; Osteoporosis; Risk Factors; Teriparatide Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000423 Date abstract record published 08/08/2012 |